Skip to main content

Mas Financial is back to its IPO valuation. Is it not worth a closer look?

 Mas Financial stock is attractive and at a similar level to its IPO valuation, which is at a steep discount to its listing level of 2017

                                              

Highlights
Underperformed Nifty in past seventy days
- No negative surprise in earnings, except for Covid provision
- Asset quality good so far, loan growth nosedives
- Effective moratorium book 13 percent of assets by value
- Near term credit cost might remain elevated

- Valuation attractive for the long-term investors

Mas Financial (CMP: Rs 661 Market Cap: Rs 3617 crore) is one of the casualties of the COVID-19 pandemic in the markets. The stock has not had a full-blown recovery; it is down 3 percent in the past seventy days compared to an 11 percent gain for the Nifty. With predominant lending to MSME and SME, the lockdown raised concerns about its asset quality. This resulted in erosion of valuation from 4X forward price to book at the time of listing in 2017 to 2.7X forward book now similar to its IPO valuation. The first quarterly update amid a near-complete lockdown showed its strength and resilience. Are investors missing an opportunity because of the stigma attached to the NBFC space?

The business

Mas Financial has stood out time and again in the past in the midst of earlier crises and has only emerged stronger. The business primarily focuses on loans to small businesses and individuals. At present there are four product categories – micro enterprise loans (MEL), SME (small & medium enterprise), two-wheeler loans and commercial vehicle (CV) loans. The company also has a housing finance subsidiary catering to affordable housing

Quarter at a glance

Source: Company

The earnings report was prima facie subdued as assets under management declined sequentially on negligible disbursements and higher collection; excess liquidity in the balance sheet suppressed interest margin and provisions shot up as the company set aside Rs 30 crore for COVID-19.

The company has gone extremely slow on disbursement and did not lend at all in April and May. It disbursed a paltry Rs 108 crore in June and Rs 88 crore in July.

Source: Company

Thanks to the moratorium, asset quality has not shown any signs of hiccups with gross and net stage 3 assets at 1.9 percent and 1.4 percent respectively, little changed from the previous quarter.

What is moratorium book suggesting?

The company had offered moratorium to all its borrowers and the collection efficiency picture has turned reassuring.

Source: Company

The crux of the bad asset story for Mas is that as on end July close to 13 percent of loans by value is not being serviced which is close to Rs 407 crore and the company is carrying COVID-19 provisions to the tune of Rs 51 crore or 12.5 percent of this vulnerable book. That is just about sufficient to cover provisions required should these loans be restructured. The total provisions on account of COVID are close to 1.6 percent of on-book assets.

Another point of comfort is that loans originated through NBFCs - close to 57 percent of the total assets and a cause for worry in earlier months - had a very high collection efficiency of 93 percent in July.

While the book is yet completely out of the woods, the signs are encouraging and we feel the company will definitely avoid a hard landing and can pass this difficult phase with a temporary increase in provisions that is more than adequately captured in our estimates.

Why should investors look at Mas?

Calibrated growth strategy

Over the last twenty five years, the company has grown its book in a calibrated manner without taking on unnecessary risk. Between FY09 to FY19, the loan book grew at a CAGR (compounded annual growth rate) of 35 percent. However, given the macroeconomic challenges, despite adequate liquidity in its balance sheet, growth slowed down in FY20 and the company has been taking a very cautious stance in recent times as the primary focus remains recovery and asset quality.

Well- funded

The company is extremely well funded and has not availed of moratorium from its lenders and has enough wherewithal to service its obligations for the next one year.

Its Capital adequacy remains strong at 34.93 percent with tier 1 capital of 32.2 percent. As on 31st July, the company had liquidity buffer of around Rs 1300 crore, unutilised cash credit facility of Rs 700 crore and sanctions on hand to the tune of Rs 1125 crore.


Source: Company

Largely a semi-urban &rural play

While COVID-19 has impacted every business and every other region, it has been felt more in urban centres. With 65 percent of the company’s books coming from rural and semi urban areas, the chances of recovering early from the crisis are high.

Housing finance subsidiary – no overt stress

Mas has a housing finance subsidiary which is into affordable housing. This company has a small asset book of Rs 284 crore and has shown no signs of asset quality deterioration so far with gross and net Stage-3 assets at 0.36 percent and 0.26 percent respectively. In terms of moratorium, as on end July, close to 17 percent of on-book assets by value was not being serviced and it carries 4.5 percent provisions on the same. This lending is secured and therefore, less of a concern.

Attractive valuations

While we acknowledge that the road ahead may not be totally smooth, the management bandwidth, excellent track record of handling multiple crises adeptly, strong capital position and adequate funding makes us believe that this temporary phase shall pass with Mas emerging stronger.

Source: Company, Moneycontrol Research

 

Valuations are attractive. They are at a level similar to its IPO valuation which is at a steep discount to its listing valuation of 2017. We feel Mas might not impress growth hungry investors, but those looking for a predictable long-term compounding story should look at gradually adding this company in their core portfolio.

Comments

Popular posts from this blog

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...

Brokerages place bets on Titan, see double-digit upside in the stock

Titan can get benefits from the strong market share in the jewellery and wrist watches segment, mainly driven by a wide range of product portfolio catering mainly to the premium and value-added designer jewellery segment. After three consecutive sessions of losses, shares of Titan Company rose over a percent in morning trade on BSE on September 23. The company was dealt a severe blow by COVID-19 as the pandemic triggered strict lockdowns completely battered the retail sector. In the calendar year so far, shares of this one of the largest, most efficient and profitable specialty retailer in India are 7 percent down. The company reported a net standalone loss of Rs 270 crore for the quarter ended June 2020 as the COVID-19 pandemic hit business. The loss was higher than a CNBC-TV18 poll estimate of Rs 175 crore. Standalone revenue during the quarter declined 62.3 percent year-on-year to Rs 1,862 crore compared to the corresponding period last fiscal. Light at the end ...

Check Chemcon Speciality Chemicals IPO allotment status in four simple steps

Equity shares will get credited into the accounts of eligible investors by September 30 and the listing of equity shares will be on October 1, 2020. Chemcon Speciality Chemicals, the manufacturer for pharmaceutical and oilfields industries, is expected to announce the basis of allotment early next week. As per the schedule provided by the company, the finalisation of the basis of the allotment will be done by September 28 and the initiation of refunds or unblocking of funds from ASBA account will take place on September 29. Equity shares will get credited to the accounts of eligible investors by September 30 and the listing will be on October The IPO comprised a fresh issue of Rs 165 crore and an offer for sale of Rs 153 crore by promoters. The company will utilise fresh issue proceeds for expansion of manufacturing facility, working capital requirements, and general corporate purposes. Chemcon manufactures specialised chemicals, such as Hexamethyldisilazane (HMDS) and Chloromethyl Iso...